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Objectives: Breast milk jaundice (BMJ) is commonly of undeter-
mined etiology. Recently, it has been shown that the degree of BMJ
was associated with the increased levels of milk-borne EGF
(Epidermal Growth Factor). The aim of the present study was to
test the effects of enteral administration of EGF on the develop-
ment of hyperbilirubinemia in neonatal rats.
Methods: Pups were divided into three groups: Group 1; artiﬁcially
fed with formula, Group 2; artiﬁcially fed with formula supple-
mented with 500 ng/ml rat EGF, Group 3; fed by their mothers.
Hyperbilirubinemia was induced by an intraperitoneal injection of
unconjugated bilirubin suspension once daily for 5 consecutive
days. Bilirubin levels, length of ideal villi, and EGF-R expression in
the intestine was determined at postnatal day 6.
Results: In the groups of 2 and 3, serum bilirubin levels were
signiﬁcantly higher when compared to animals in the group 1.
There was no signiﬁcant difference in terms of serum bilirubin
levels between the Group 2 and Group 3. Length of ileal villi was
signiﬁcantly longer in the Group 2 and Group 3 than the Group 1
animals. The pattern of EGF-R expression in the Group 2 was
similar to that seen in Group 3 animals. In contrast, animals given
formula without EGF had markedly decreased expression of the
EGF-R.
Conclusion: Results suggest that EGF supplementation in newborn
rats leads to a signiﬁcant increase in intestinal mucosal prolifera-
tion and a signiﬁcant decrease in bilirubin elimination. These data
suggest that EGF possibly increases intestinal bilirubin absorption; fax: þ90 232 259 05 41.
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Further studies are needed to conﬁrm this hypothesis.
© 2015 Published by Elsevier Ltd on behalf of European Society for
Clinical Nutrition and Metabolism. This is an open access article
under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Breast milk jaundice (BMJ) is characterized by prolonged unconjugated hyperbilirubinemia in
otherwise healthy infants. Even the mechanism of breast milk jaundice is not completely clear, several
substances present in milk are involved in the pathogenesis: pregnan-3a-20b-diolon, hepatic glu-
curoniltransferase inhibitor, inﬂammatory cytokines, EGF (epidermal growth factor), which could
cause reduced intestinal motility and increased bilirubin resorption [1,2].
The introduction of enteral nutrition initiates signiﬁcant changes in mucosal structure and function
required for the utilization of milk. Physiologic changes in digestive and absorptive processes are well
described, but the understanding of the mechanisms by which intestinal growth and epithelial turn-
over are regulated remains fragmentary [3]. In vivo and in vitro studies showed that human milk
stimulates intestinal development, DNA synthesis, and cell proliferation. EGF is one of the most
important growth-stimulating peptides that augments intestinal epithelial cell proliferation and dif-
ferentiation and is secreted by multiple cells throughout the gastrointestinal system into the intestinal
lumen. It is supplied by amniotic ﬂuid throughout pregnancy, whereas the infant in the postnatal
period relies on the signiﬁcant concentrations of EGF found in human milk and colostrum [4,5].
Because EGF is detected in several mammalian milks, questions have been raised about its functional
signiﬁcance. Previous studies demonstrated the presence of EGF in the developing gut of suckling rats
and showed that intestinal EGF levels are predominantly related to the intake of milk-borne EGF [6].
Studies have demonstrated the ability of EGF to preserve intestinal barrier function, increase intestinal
enzyme activity, and improve nutrient transport [7]. The biologic actions of EGF are mediated through
binding to its speciﬁc receptor, EGF receptor (EGF-R), which is distributed throughout the fetal and
neonatal gastrointestinal tract [8]. In a previous clinical study, we have suggested that the degree of
BMJ was associated with the increased levels of milk-borne EGF. In the aforementioned study, the
concentrations of EGF were higher in the breast milk of the mothers whose infants had BMJ and the
milk concentrations of EGF were signiﬁcantly correlated with neonatal bilirubin and blood EGF con-
centrations [9].
The aim of the present study was to test the effects of EGF supplementation on the development of
hyperbilirubinemia in neonatal rats. We hypothesized that enteral administration of EGF could in-
crease the development of neonatal hyperbilirubinemia and the effect of EGF could be mediated
through interaction with the EGF-R at the site of intestinal maturity.
2. Materials and methods
2.1. Animals
This study was performed in accordance with the guidelines provided by the Experimental Animal
Laboratory and approved by the Animal Care and Use Committee of the Dokuz Eylul University, School
of Medicine. Twenty-one 1-day-old Wistar albino rat pups were used for all experiments.
2.2. Experimental design
Newborn rats were collected from their mothers immediately after birth to prevent suckling of
maternal milk. Animals were weighed and then placed in an infant incubator to control body tem-
perature and assigned to three experimental groups: Group 1; artiﬁcially fed with growth factor-free
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500 ng/ml rat EGF (Harlan Bioproducts, Indianapolis, IN), or Group 3; littermates fed by their mothers
(dam fed). Artiﬁcially fed pups were hand fed 150 mL of milk formula every 3 h [10].
Artiﬁcially hyperbilirubinemic Wistar rats were obtained according to previous studies [10].
Hyperbilirubinemia in Wistar rats (n ¼ 21) was induced by a bolus injection of unconjugated hyper-
bilirubinemia (UCB) suspension into the peritoneal cavity once daily for 5 consecutive days (4 mg in
1 mL/100 g body weight/day). UCB was dissolved in 0.1 M NaOH and titrated to pH 7.8 with 0.1 M HCl.
After 5 day, all surviving animals were anesthetized with inhalation of eter [11]. Blood was drawn
for bilirubin analyses, and the animals euthanized by exsanguination. The total small intestine was
harvested for microscopic analysis. To evaluate sections from ileum were collected from each animal
for histological measurements.
2.3. Total bilirubin levels
Blood samples were collected via a cheek puncture into an 85 mL heparinized hematocrit tube.
Samples were centrifuged and the hematocrit (Hct) was measured. The plasma was collected and
analyzed for plasma bilirubin level using a Leica Unistat Bilirubinometer (Reichert, Inc., Depew, NY).
This requires approximately 25 mL of plasma/analysis, thus 50e80 mL of blood were taken for each
measurement. Hct and total bilirubin (TB) were recorded for each blood sample. Because of the small
size of the animals, a maximum of two blood samples were drawn from each animal.
2.4. Light microscopic examination
Tissue samples were ﬁxed in 10% phosphate buffered formalin than processed for embedding in
parafﬁn wax by routine protocol. The slides were examined using a light microscope (Olympus BH-2,
Tokyo, Japan). Images were processed with Image Tool for windows version 3.0 Copyright @2002 (The
University of Texas Health Science Center, San Antonio), modiﬁed from that described previously [12].
In each case, 10 high power ﬁeld images (total villi length; 400 mm) were selected, and acquisition and
digitalization were performed.
2.5. Immunohistochemical assessment
Immunohistochemical staining was performed using the streptavidin/biotin method. The immu-
nohistochemistry procedure for EGF-R (sc-03: Santa Cruz, USA) was performed. The images were
analyzed by using a computer-assisted image analyzer system consisting of a microscope (Olympus
BH-2, Tokyo, Japan) equipped with a high-resolution video camera (JVC TK-890E, Japan). All sections
were scored in a semi quantitative fashion, which considered both the intensity and percentage of cells
staining at each intensity.
For each slide, a minimum of 5 ﬁelds were examined and assigned for severity of changes using
scores of none (), mild (þ), moderate (þþ), and strong (þþþ) [13].
2.6. Statistical analysis
Statistical comparison between the groups in terms of bilirubin levels, length of villus surface, and
EGF-R expression score were performed by one-way ANOVA and Tukey's test (SPSS 15.0, Chicago, IL,
USA). A probability level (p) of 0.05 or less was chosen to represent statistical signiﬁcance.
3. Results
Intraperitoneal injection of UCB to breastfed Wistar rats led to marked elevation of serum bilirubin
levels from 0.8 ± 0.1 to 102 ± 10 micromol/L in Group 3 animals (p < 0.001). In Group 2, which was fed
with artiﬁcial formula with EGF, resulted in a signiﬁcant increase in serum bilirubin levels when
compared to Group 1 animals that was fed with artiﬁcial formula without EGF (56 ± 8 versus
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Group 2 and Group 3 animals (p > 0.05) (Table 1).3.1. Histopathological examination
The general appearance of enterocytes from all of the three groups was similar. No ultrastructural
abnormalities were noted in any of the groups. Cell membranes and cellular organelles appeared
normal. Microvilli appeared normal and of equal numbers and density. Length of ileal villi were
signiﬁcantly increased in both Group 2 and Group 3 compared to Group 1 animals (Table 1).3.2. Histological localization of the EGF-R
Histological examination of ileal samples from dam fed pups revealed high levels of EGF-R
expression in the apical and basolateral membranes of the villi. The pattern of EGF-R localization in
the cow's milk-based formula supplemented with rat EGF group was similar to that seen in dam fed
animals (EGF-R expression score, p ¼ 0.28), except that there was very strong staining of the apical
membrane and moderate staining of the basolateral membrane of the villi enterocytes. In contrast,
animals given EGF-free milk-based formula had markedly decreased expression of the EGF-R (EGF-R
expression score, p ¼ 0.04) in the apical and basolateral membranes of the villi compared with the
cow's milk-based formula supplemented with rat EGF group (Table 1, Fig. 1).
4. Discussion
EGF is thought to enhance intestinal absorption during the neonatal period. Therefore, increased
levels of EGF may offer a plausible mechanism for increased bilirubin absorption in the gut and
resultant unconjugated hyperbilirubinemia in breast milk jaundice [2]. A recent clinical study by our
study group demonstrated a positive correlation between unconjugated bilirubin levels in exclusively
breastfed infants and EGF levels in the serum of infants and in the breast milk of their mothers [9]. In
the present study, we observed a signiﬁcant reduce in bilirubin levels in the group artiﬁcially fed with
growth factor-free cow's milk-based formula on P6. As a continuation of the previous work, this study
provides new clues on EGF and hyperbilirubinemia relation.
Recently, Xiao et al. investigated the changes in EGF concentrations in infants' serum and breast
milk in neonates with late-onset breast milk jaundice after stopping breastfeeding [14]. Their results
demonstrated that total bilirubin and EGF concentrations in infants' serum were signiﬁcantly
decreased 72 h after stopping breast-feeding. Consistent with our previous results, their results indi-
cated a possible relation between breast milk derived EGF and serum bilirubin levels. Interestingly, the
present experimental study seems to be a reverse control of these clinical studies and further supports
this relationship by demonstrating that EGF supplementation enlarged intestinal absorption surface,
boosted EGF-R expression and increased serum bilirubin levels.
EGF is critical to the maturation and healing of the intestinal mucosa. EGF is resistant to low pH and
digestive enzymes, allowing it to pass through the stomach to the intestine, where it stimulates theTable 1
The effect of EGF supplement on blood bilirubin levels, length of villus surface and EGF-R expression score.
Groups Blood bilirubin levels (micromol/L)a Length of villus surfacea EGF-R expression scorea
Group 1 56 ± 8 1183.79 ± 68.27 0.57 ± 0.3
Group 2 97 ± 8 2472.01 ± 191.54 2.33 ± 0.57
Group 3 102 ± 10 3125.40 ± 248.70 2.7 ± 0.5
P values
Groups 1 v.s 2 0.01 0.019 0.04
Groups 2 v.s 3 0.09 0.055 0.28
Groups 1 v.s 3 0.0001 0.017 0.01
a The values are presented as mean ± SD.
Fig. 1. Representative light microscopic images of quantitative histopathological assessments of patterns of EGF-R immunoreac-
tivity. The pattern of EGF-R localization in the cow's milk-based formula supplemented with rat EGF group (E, F) was similar to that
seen in dam fed animals (A, B). In contrast, animals given cow's milk-based formula had markedly decreased expression of the EGF-R
(C, D).
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synthesis [15,16]. There are multiple protective mechanisms of action for EGF in the infant intestine,
including inhibition of programmed cell death, and correcting alterations in intestinal and liver tight
junction proteins induced by pro-inﬂammatory TNF-a [17]. In this study, groups 2 and 3 (EGF received
groups, via breast milk or supplemental), showed higher length of ileal villi compared to group-1 that
fed artiﬁcially without EGF. Intestinal surface area was not signiﬁcantly different between the groups 2
and 3. The ﬁndings, indicating the stimulating effect of EGF (either supplemental, or naturally occur-
ring in breast milk) on intestinal mucosal growth and EGF-R expression, were compatible with the
increased bilirubin levels in EGF groups (Group 2 and Group 3). It may be assumed that EGF leads to
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and increased intestinal absorption. However, this is the ﬁrst in vivo study indicating the effect of EGF
on bilirubin elimination, and further studies are warranted to understand the effects of EGF on
enterocyte bilirubin metabolism.
Various studies in the past have described the appearance of EGF-R in the human digestive tract
between the 12th and 17th weeks of gestation [18,19]. EGF-Rs, present throughout the gastrointestinal
tract on the basolateral membrane, promote intestinal growth and stimulates intestinal repair [20,21].
It has been demonstrated that EGF maintains intestinal integrity and protects intestinal epithelium
against NEC injury by alteration of the balance between pro-and anti-apoptotic proteins in the site of
injury [21e23]. In this study, results demonstrate that EGF supplementation increases blood bilirubin
levels and that the hyperbilirubinemic effect of EGF is associated with its ability to increase the
expression of EGF-R in the neonatal rat ileum. Moreover, the increased expression of EGF-R in the
ileum indicates that the healing effect of exogenous EGF is mediated directly at the site of intestinal
maturity and permeability.
In this study, a dose of 500 ng/ml EGF was chosen, according to the previous studies, which used
enteral EGF for the prevention of necrotizing enterocolitis in newborn rats. Themost efﬁcient dosage of
EGF reducing experimental NEC was found 500 ng/ml in these studies, and this was suggested as
physiological supplemental dosage [22,23].
There are a few limitations of this study. One of the most important limitations is that, we used
artiﬁcial jaundiced rats in this experiment. However this may not fully reﬂect the breast milk jaundice.
The other important limitations were that, unfortunately, we were not able to measure the stool
bilirubin levels and we couldn't investigate the dose dependent effects of EGF on hyperbilirubinemia.
In summary, results indicate that EGF may be an important factor for development of hyper-
bilirubinemia in the suckling period, and possibly modulates bilirubin elimination by inducing intes-
tinal mucosal proliferation and increasing bilirubin absorption. More detailed studies are needed to
assess the effects of EGF on the intestinal bilirubin metabolism.
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